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PMP Communication Module
In August 2019, the communication module of the 
Iowa Prescription Monitoring Program (PMP) went live. 
This module’s notable features include Care Notes and a 
clinician-to-clinician direct messaging client. Care Notes 
are included in the NarxCare report and allow clinicians to 
append notes to the PMP record of a patient. These notes 
only become visible on the PMP report if clinicians have 
the communications module enabled. To create a new Care 
Note for a patient:
 ♦ Generate a NarxCare report for the patient.
 ♦ Within the report, there is a new section for Care 
Notes. Click “add note” to open the Care Note 
creation screen. 
 ♦ Within a Care Note, you can also attach relevant 
documents, such as a pain contract or pharmacy lock-
in information. Clinicians will also be able to set an 
expiration date for their Care Notes. Some electronic 
health record (EHR) integrations with the PMP will 
have a “share note” field, which is used to indicate 
whether a note should be shared with any authorized 
PMP user or only internally within your organization. 
Clinicians and state PMP administrators also have 
the ability to edit their own Care Notes within the 
PMP. When viewing a patient’s Care Notes, new 
notes will be displayed in bold until viewed. There 
is a mechanism in place for flagging a message/Care 
Note as inappropriate, to be submitted for review by 
a state PMP administrator. 
The clinician-to-clinician direct messaging allows 
clinicians to communicate directly through the NarxCare 
component of the PMP. This feature also allows for 
information to be exchanged between clinicians regarding 
a single patient. Within the dashboard of the PMP there is 
now an inbox, which includes both the clinician’s messages 
and the Care Notes that have been written. To send a 
message to another clinician through the PMP, first generate 
a NarxCare report for the patient, then, when viewing the 
Rx Graph section of the report, click on the prescriber(s) 
that you wish to message to begin the process. When a 
message is sent to another clinician regarding a patient, it 
automatically includes the NarxCare report for that patient. 
More information regarding these new modules and 
instructions for use can be found at https://pharmacy.iowa 
.gov/iowa-pmp-awarxe.
Naloxone Administration Reporting Now 
Live in the Iowa PMP
Effective July 1, 2018, Iowa first responders (eg, 
emergency medical services, paramedics, firefighters, 
and police) were required to report the administration of 
a rescue opiate antagonist (eg, naloxone, Narcan®) to the 
state. These opioid antagonist administrations are now 
included in the Iowa PMP as part of the patient NarxCare 
report. The naloxone administration indicator (NAI), 
when present, will be displayed for providers and can be 
accessed via the Iowa PMP AWARXE portal, or through 
existing EHR integrations using PMP Gateway. If an NAI 
is present, authorized providers may click on the indicator 
to view additional details of the event(s), including the date 
and who administered the naloxone. The NAI is meant to 
provide additional insight into a patient’s history as a tool to 
help you make informed clinical decisions for your patient.
Iowa PMP Field Audit Project
The Iowa PMP will soon begin an innovative project to 
audit prescriptions reported to the Iowa PMP. The audit will 
utilize a “field audit” approach and will include compli-
ance officers collecting copies of controlled substance (CS) 
prescriptions as part of their routine inspections. The Iowa 
PMP hopes to formally initiate the project in July 2020. The 
audit results will be used to establish baseline reliability 
and validity of the Iowa PMP data as well as monitor and 
evaluate changes and trends over time.   
help promote quality compounding practices and better 
address emerging public health concerns that may affect 
patients.”
FDA Clarifies Compounding Rules, 
Offers Flexibility to Help Ease Drug 
Shortages During COVID-19 Pandemic
FDA noted it will use discretion in enforcing certain 
standards related to 503A and 503B compounding in 
an effort to ease drug shortages during the coronavirus 
disease 2019 (COVID-19) pandemic. During an 
American Pharmacists Association (APhA) webinar on 
April 30, 2020, the agency clarified it will “look to 503B 
compounders to grapple with drug shortages” and “turn 
to 503A compounders to fill in the gaps.”
In addition, the agency clarified that medications on 
the FDA drug shortage list are effectively considered “not 
commercially available,” which frees 503A and 503B 
compounding facilities from limits on compounding 
drugs that are “essentially a copy” of a product already 
available on the market. FDA also does not intend to take 
action if a 503A facility fills orders for a compounded 
drug that is essentially a copy of an approved drug that 
has been discontinued and is no longer marketed.
In April 2020, FDA issued a temporary guidance that 
granted flexibility for pharmacists to compound certain 
necessary medications under 503A for nonspecific 
patients hospitalized due to COVID-19. In addition, a 
temporary guidance was issued that granted enforcement 
flexibility for 503B outsourcing compounding facilities 
for drugs in shortage for patients hospitalized during 
the COVID-19 public health emergency. The guidance 
documents stipulate the conditions compounders 
must meet and are available at https://www.fda.gov/
media/137125/download. 
More information on these compounding rule 
clarifications is available in a May 5, 2020 press release 
on the APhA website.
CMS Allows Pharmacies to Temporarily 
Enroll as Clinical Diagnostic 
Laboratories for COVID-19 Testing
Centers for Medicare & Medicaid Services (CMS) 
has released a document detailing a process that allows 
pharmacies to temporarily enroll as independent clinical 
diagnostic laboratories. This process will allow those 
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FDA Releases MOU on Human 
Drug Compounding Regulation and 
Oversight
Acknowledging the vital role states play in reducing 
the risks associated with compounded drugs, Food 
and Drug Administration (FDA) has made available a 
Final Standard Memorandum of Understanding (MOU) 
Addressing Certain Distributions of Compounded Human 
Drug Products, intended to be entered into between the 
agency and the states. The release of the MOU is required 
as part of its submission to the Office of Management and 
Budget for review and clearance under the Paperwork 
Reduction Act of 1995. The MOU was developed in close 
consultation with the National Association of Boards of 
Pharmacy®(NABP®), as described in the Federal Food, 
Drug, and Cosmetic Act. The agency also engaged with 
states, pharmacies, associations, pharmacists, and other 
stakeholders.
Among the issues addressed in the MOU is the 
definition of the statutory term “inordinate amounts,” 
which refers to compounded drugs that are distributed 
interstate. In addition, the MOU includes the risk-based 
oversight model from the 2018 revised draft MOU. 
States that sign the document agree to identify pharmacy 
compounders that distribute inordinate amounts (greater 
than 50%) of compounded drug products interstate, as 
well as report certain information to FDA about those 
compounders. FDA also provided clarity in the MOU 
on state investigations of complaints associated with 
compounded drugs distributed out of state. States that 
enter into the MOU will investigate complaints about 
drugs compounded at a pharmacy within their state and 
distributed outside of the state and advise FDA when they 
receive reports of serious adverse drug experiences or 
serious product quality issues, like drug contamination.
To help states to better investigate these issues, FDA 
has also announced an agreement with NABP to make 
an information sharing network available to the states. 
Through this network, states will be able to obtain infor-
mation from pharmacies in their states and transmit that 
information to FDA.
“We anticipate the final MOU, once signed, will help 
to facilitate increased collaboration between the FDA 
and the states that sign it,” said Janet Woodcock, MD, 
Director, Center for Drug Evaluation and Research, 
in an FDA Voices article. “Working together, we can 
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facilities to seek Medicare reimbursement for COVID-19 
tests, making it easier for them to provide that service 
during the pandemic.
“Up until this point in time, most pharmacies could 
only offer this as a cash service because they were not 
considered providers through CMS, and really a lot of 
the third-party payers really didn’t have an interest in a 
fee-for-service type model,” said Michael E. Klepser, 
PharmD, FCCP, pharmacy professor at Ferris State 
University, in an interview with Bloomberg Law. “The 
fact that CMS is saying we’re now authorizing or 
allowing pharmacists to get reimbursed for these is a 
great door opening at the federal level and that’s a huge, 
huge thing.”
Chain pharmacies such as CVS, Walgreens, and Rite 
Aid are offering drive-through testing at many pharmacies 
throughout the country.
FDA Issues Updated Guidance 
for Compounding Pharmacies 
Experiencing PPE Shortages
FDA has issued an update for its guidance to pharmacy 
compounders that may experience shortages of personal 
protective equipment (PPE) during the COVID-19 
pandemic. As compounders typically utilize PPE when 
performing sterile compounding, the updated guidance 
clarifies that the drugs can be compounded under the 
policy in a segregated compounding area that is not in 
a cleanroom. This policy has been adopted to ensure 
patients continue to have access to medicines they 
need during the pandemic, and to reduce the risks of 
compounding when standard PPE is not available.
In addition to FDA guidance, United States Pharmaco-
peial Convention has previously issued an informational 
document for compounders regarding garb and PPE short-
ages during the pandemic. The document includes recom-
mendations for conserving garb and PPE and what steps 
might be considered in the case of shortages of garb and 
PPE used for both sterile and nonsterile compounding.
The updated guidance can be accessed through 
FDA’s website by visiting www.fda.gov/media/136841/
download. 
HHS Expands Telehealth Access in 
Response to COVID-19
In an effort to prevent and respond to the COVID-19 
pandemic, the US Department of Health and Human 
Services (HHS) has awarded $20 million to increase 
telehealth access and infrastructure for health care 
providers and families. The funds, which are awarded 
through the Health Resources and Services Administration 
(HRSA), will increase capability; capacity and access 
to telehealth and distant care services for providers, 
pregnant women, children, adolescents, and families; 
and assist telehealth providers with cross-state licensure.
“This new funding will help expand telehealth 
infrastructure that is already being used during the 
pandemic to provide essential care, especially to the most 
vulnerable, including pregnant women and children with 
special health care needs,” said HHS Secretary Alex Azar 
in a press release. “This funding will also help clinicians 
use telehealth nationally by streamlining the process to 
obtain multi-state licensure.”
HRSA’s Maternal and Child Health Bureau awarded 
a total of $15 million to four recipients; each award sup-
ports a key area in maternal and child health, including 
pediatric care, maternal health care, state public health 
systems, and family engagement for children with special 
health care needs. HRSA’s Federal Office of Rural Health 
Policy awarded a total of $5 million to two recipients 
through the Licensure Portability Grant Program, which 
will assist telehealth clinicians nationally on licensure 
and credentialing to meet emerging needs related to 
COVID-19.
Criminals Found Posing as CDC 
Representatives to Steal Money and 
Information
Centers for Disease Control and Prevention (CDC) 
is warning the general public of a new type of phone 
and phishing scam by criminals posing as CDC 
representatives, often requesting donations. According 
to CDC, most of these fraudulent activities are being 
conducted by phone, utilizing software to “spoof” phone 
calls to make them appear as if they are coming from 
phone numbers that may look familiar. CDC advises 
consumers to avoid answering calls from numbers they do 
not recognize, and to avoid sharing personal information 
over the phone. In addition, CDC notes that no federal 
agency will request donations from the general public. 
Suspicious phone calls may be reported to the Federal 
Communications Commission.
More information on the scams is available on the CDC 
website at https://www.cdc.gov/media/phishing.html. 
National Pharmacy Compliance News July 2020
Page 4
continued on page 5
Naloxone Dispensing Program
The Iowa Board of Pharmacy, in collaboration with the 
Iowa Department of Public Health, plans to initiate and 
support a statewide naloxone distribution program. All 
community pharmacies across the state of Iowa will be 
permitted to participate and will be able to submit claims 
for naloxone (Narcan) nasal spray to a claims processor 
utilizing a BIN and PCN. Pharmacies will be reimbursed 
the cost of the Narcan nasal spray at the state Medicaid 
rate, plus a $20 dispensing fee. More information will be 
forthcoming as the project kicks off.
Governor Reynolds Signs Bills Into Law
On Monday, June 1, 2020, Governor Kim Reynolds 
signed Senate File (SF) 2119 and SF 2120 into law. SF 
2119 makes updates to Iowa’s Controlled Substances Act 
to codify substances that were temporarily scheduled by 
the Board through rulemaking. The bill also provides more 
general language regarding the scheduling or descheduling 
of Food and Drug Administration-approved cannabis-
derived products. 
SF 2120 provides clarity that veterinarians, although 
not required, may access the PMP. The bill also provides 
for the required reporting of Schedule V CS to the PMP.
The Board will be promulgating rules to implement the 
legislation. 
Iowa PMP Update With CE On-Demand 
Webinar Now Live
Modernizing the PMP: Updates to the Iowa 
PMP – 2020
The course highlights recent enhancements made to 
Iowa’s PMP. Specific topics include a brief introduction 
to the communications module and proactive or threshold 
reports, as well as a review of NarxCare – an advanced 
opioid use disorder management platform designed 
to provide prescribers and pharmacists with insights 
into patient prescription fill histories and behaviors. 
Additionally, a summary of House File 2377, commonly 
referred to as the “opioid bill,” and its continued impact on 
clinical practice in the state of Iowa are discussed.
Visit the following links for the pharmacy and pharmacy 
technician courses.     
 ♦ Pharmacists – https://learn.ceimpact.com/library/
course/2070. 
 ♦ Pharmacy Technicians – https://learn.ceimpact.com/
library/course/2104.
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Why Has the Option for ‘Other’ Been 
Removed on DEA Form 106?
If your pharmacy has had the unfortunate situation of 
discovering a loss or theft of CS recently, you may have 
noticed that the option to report the type of loss as “other” 
is no longer available on Drug Enforcement Administration 
(DEA) Form 106. The change to the form was made at DEA 
headquarters and was intended to ensure that pharmacies 
are accurately reporting a loss of CS. The purpose of 
DEA Form 106 is not, and was never, intended to serve 
as a reconciliation tool or to identify a record-keeping 
discrepancy. The reporting form is intended to report to 
DEA when CS have been diverted from the registrant’s 
location. 
DEA’s stance is that a pharmacy should be able to identify 
and account for what happens to the CS under its control, 
so there should never be a time that a pharmacy simply 
cannot account for a discrepancy. If the pharmacy discovers 
a discrepancy in the inventory of a CS where diversion 
cannot be determined, the pharmacy should document the 
discrepancy and be prepared to provide an explanation to 
DEA but should not submit a DEA Form 106. DEA Form 
106 is intended for known diversion by way of robbery, 
break-in, known employee pilferage, etc. 
It is also important when completing DEA Form 106 in 
cases of known diversion to accurately identify the method 
of diversion. 
 ♦ If the pharmacy is closed at the time of the diversion, 
the method of diversion would be a break-in. 
 ♦ If the pharmacy is open at the time of the diversion, 
the method of diversion would be a robbery (not 
customer theft), regardless of the threat or use of a 
weapon. 
 ♦ For cases of internal employee diversion, the method 
of diversion would be employee pilferage, but this 
should only be utilized if you can determine the 
identity of the individual responsible for the diversion 
or can be assured that the diversion was the result of 
employee pilferage. Do not simply select employee 
pilferage for lack of a better (“other”) option.
Failure to Report – Theft or Loss of CS
Part of the responsibilities of being a licensee or 
registrant of the Board is notifying the Board when 
another licensee or registrant has violated laws, rules, or 
regulations. In particular, one situation where the Board 
finds this notice is lacking is when a licensee or registrant 
is responsible for the loss of CS. The Board routinely 
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receives a DEA Form 106 that reports theft or loss of CS 
with the reason identified as “employee pilferage.” In these 
situations, however, the Board is to be notified immediately 
of theft or loss when a licensee or registrant is responsible 
for the theft or loss (see Iowa Administrative Code (IAC) 
657-10.21(1)). The pharmacy is responsible for providing 
this immediate notice to the Board, but a corresponding 
liability rests with the pharmacist-in-charge (PIC) or other 
pharmacy staff members who are obligated to notify the 
Board of such acts by another licensee or registrant (see 
IAC 657-36.6(17)).
Required Elements on Prescriptions 
Issued by Physician Assistants
During the 2020 session of the Iowa Legislature, SF 
2357 was passed and signed by Governor Reynolds, which 
addresses the practice of physician assistants (PAs). Among 
the changes, the requirement that a prescription issued by 
a PA contain the name of the supervising physician has 
been removed. The bill was effective upon the governor’s 
signature on March 18, 2020. Prescriptions issued by a PA 
are no longer required to include the name of the supervising 
physician.
Is It Legit? Verifying Licensure of 
Wholesale Distributors
While pharmacies have always been accustomed to 
periodic drug shortages, the current coronavirus disease 
2019 pandemic has resulted in supply issues of numerous 
commonly dispensed prescription medications that may 
seem more critical than usual. When availability of 
important drugs is limited, there is a prime opportunity for 
new secondary wholesalers to enter the market. Although 
there are many reputable secondary wholesalers, others 
exist strictly to participate in the gray market. Emails and 
faxes from secondary wholesalers are making their way into 
pharmacies offering up products that are in short supply. But 
how can you be sure such offers are legitimate and that the 
wholesaler is authorized to distribute into the state of Iowa?
It is the responsibility of each pharmacy and its PIC to 
ensure that all prescription drugs and devices purchased 
come from an Iowa-licensed wholesale distributor. 
Verification can be accomplished online or by contacting 
the wholesaler directly to request a copy of its Iowa wholesale 
distributor license certificate. Starting in January 2019, the 
Board began requiring all wholesale drug distributors to 
obtain Drug Distributor Accreditation (formerly known as 
Verified-Accredited Wholesale Distributors® accreditation) 
as a condition of licensure. While the Drug Distributor 
Accreditation approval process is rigorous, it is a key factor 
in preventing counterfeit drugs from finding their way into 
Iowa pharmacies. 
Exert due diligence if you are considering obtaining 
prescription medications from a source other than your 
usual vendor. Any questions regarding wholesaler 
verification can be directed to the Board compliance officer 
assigned to your pharmacy. 
